Ann Marie Navar-Boggan1, Eric D Peterson2, Ralph B D'Agostino2, Benjamin Neely2, Allan D Sniderman2, Michael J Pencina2. 1. From the Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (A.M.N.-B., E.D.P., B.N., M.J.P.); Boston University, Boston, MA (R.B.D.); and Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, Canada (A.D.S.). navar006@mc.duke.edu michael.pencina@duke.edu. 2. From the Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (A.M.N.-B., E.D.P., B.N., M.J.P.); Boston University, Boston, MA (R.B.D.); and Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, Canada (A.D.S.).
Abstract
BACKGROUND: Many young adults with moderate hyperlipidemia do not meet statin treatment criteria under the new American Heart Association/American College of Cardiology cholesterol guidelines because they focus on 10-year cardiovascular risk. We evaluated the association between years of exposure to hypercholesterolemia in early adulthood and future coronary heart disease (CHD) risk. METHODS AND RESULTS: We examined Framingham Offspring Cohort data to identify adults without incident cardiovascular disease to 55 years of age (n=1478), and explored the association between duration of moderate hyperlipidemia (non-high-density lipoprotein cholesterol ≥ 160 mg/dL) in early adulthood and subsequent CHD. At median 15-year follow-up, CHD rates were significantly elevated among adults with prolonged hyperlipidemia exposure by 55 years of age: 4.4% for those with no exposure, 8.1% for those with 1 to 10 years of exposure, and 16.5% for those with 11 to 20 years of exposure (P<0.001); this association persisted after adjustment for other cardiac risk factors including non-high-density lipoprotein cholesterol at 55 years of age (hazard ratio, 1.39; 95% confidence interval, 1.05-1.85 per decade of hyperlipidemia). Overall, 85% of young adults with prolonged hyperlipidemia would not have been recommended for statin therapy at 40 years of age under current national guidelines. However, among those not considered statin therapy candidates at 55 years of age, there remained a significant association between cumulative exposure to hyperlipidemia in young adulthood and subsequent CHD risk (adjusted hazard ratio, 1.67; 95% confidence interval, 1.06-2.64). CONCLUSIONS: Cumulative exposure to hyperlipidemia in young adulthood increases the subsequent risk of CHD in a dose-dependent fashion. Adults with prolonged exposure to even moderate elevations in non-high-density lipoprotein cholesterol have elevated risk for future CHD and may benefit from more aggressive primary prevention.
BACKGROUND: Many young adults with moderate hyperlipidemia do not meet statin treatment criteria under the new American Heart Association/American College of Cardiology cholesterol guidelines because they focus on 10-year cardiovascular risk. We evaluated the association between years of exposure to hypercholesterolemia in early adulthood and future coronary heart disease (CHD) risk. METHODS AND RESULTS: We examined Framingham Offspring Cohort data to identify adults without incident cardiovascular disease to 55 years of age (n=1478), and explored the association between duration of moderate hyperlipidemia (non-high-density lipoprotein cholesterol ≥ 160 mg/dL) in early adulthood and subsequent CHD. At median 15-year follow-up, CHD rates were significantly elevated among adults with prolonged hyperlipidemia exposure by 55 years of age: 4.4% for those with no exposure, 8.1% for those with 1 to 10 years of exposure, and 16.5% for those with 11 to 20 years of exposure (P<0.001); this association persisted after adjustment for other cardiac risk factors including non-high-density lipoprotein cholesterol at 55 years of age (hazard ratio, 1.39; 95% confidence interval, 1.05-1.85 per decade of hyperlipidemia). Overall, 85% of young adults with prolonged hyperlipidemia would not have been recommended for statin therapy at 40 years of age under current national guidelines. However, among those not considered statin therapy candidates at 55 years of age, there remained a significant association between cumulative exposure to hyperlipidemia in young adulthood and subsequent CHD risk (adjusted hazard ratio, 1.67; 95% confidence interval, 1.06-2.64). CONCLUSIONS: Cumulative exposure to hyperlipidemia in young adulthood increases the subsequent risk of CHD in a dose-dependent fashion. Adults with prolonged exposure to even moderate elevations in non-high-density lipoprotein cholesterol have elevated risk for future CHD and may benefit from more aggressive primary prevention.
Authors: Ramachandran S Vasan; Joseph M Massaro; Peter W F Wilson; Sudha Seshadri; Philip A Wolf; Daniel Levy; Ralph B D'Agostino Journal: Circulation Date: 2002-01-01 Impact factor: 29.690
Authors: Paul N Hopkins; Gerardo Heiss; R Curtis Ellison; Michael A Province; James S Pankow; John H Eckfeldt; Steven C Hunt Journal: Circulation Date: 2003-07-07 Impact factor: 29.690
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto Journal: JAMA Date: 1998-05-27 Impact factor: 56.272
Authors: Jarett D Berry; Kiang Liu; Aaron R Folsom; Cora E Lewis; J Jeffrey Carr; Joseph F Polak; Steven Shea; Stephen Sidney; Daniel H O'Leary; Cheeling Chan; Donald M Lloyd-Jones Journal: Circulation Date: 2009-01-12 Impact factor: 29.690
Authors: Michael J Pencina; Ralph B D'Agostino; Martin G Larson; Joseph M Massaro; Ramachandran S Vasan Journal: Circulation Date: 2009-06-08 Impact factor: 29.690
Authors: Michael M Mendelson; Asya Lyass; Christopher J O'Donnell; Ralph B D'Agostino; Daniel Levy Journal: JAMA Cardiol Date: 2016-04-01 Impact factor: 14.676
Authors: Kausik K Ray; Robert M Stoekenbroek; David Kallend; Toshiyuki Nishikido; Lawrence A Leiter; Ulf Landmesser; R Scott Wright; Peter L J Wijngaard; John J P Kastelein Journal: JAMA Cardiol Date: 2019-11-01 Impact factor: 14.676
Authors: Josiane B S Braun; Jader B Ruchel; Alessandra G Manzoni; Fátima H Abdalla; Emerson A Casalli; Lívia G Castilhos; Daniela F Passos; Daniela B R Leal Journal: Mol Cell Biochem Date: 2017-11-29 Impact factor: 3.396
Authors: Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2017-01-25 Impact factor: 29.690